$6.17
Value $386M
AGEN and JNJ stock compared: price, dividend, valuation and results, from SEC filings.
$6.17
Value $386M
$271.31
Value $654B
Agenus (AGEN) has a market value of $386M and Johnson & Johnson (JNJ) $654B. Over the last year, with dividends, AGEN moved +46.9% and JNJ +36.9%. The P/E is 13.1 for AGEN and 40.6 for JNJ. Dividend yield: AGEN none, JNJ 1.95%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
AGEN$386M
JNJ$654B
JNJ is 1,692 times AGEN
Revenue, 12 months
AGEN$134M
JNJ$99.3B
JNJ is 742 times AGEN
Net income, 12 months
AGEN$29M
JNJ$16.1B
JNJ is 546 times AGEN
Operating margin
AGEN38.9%
JNJ–
ROIC
AGEN–
JNJ12.4%
P/E
AGEN13.1
JNJ40.6
JNJ is 3.1 times AGEN
Dividend yield
AGEN0.0%
JNJ2.0%
2.0 points apart
5-year return
AGEN-90.8%
JNJ+91.4%
182.2 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
AGEN-90.8%
JNJ+91.4%
| Period | AGENWith dividends | JNJWith dividends |
|---|---|---|
| 1 year since November 19, 2025 | +46.9%Price +46.9% | +36.9%Price +33.9% |
| 3 years since November 20, 2023 | -58.3%-25.3% a yearPrice -58.3% | +95.5%+25.0% a yearPrice +80.9% |
| 5 years since November 19, 2021 | -90.8%-38.0% a yearPrice -90.8% | +91.4%+13.9% a yearPrice +66.5% |
| 10 years since November 21, 2016 | -93.5%-23.9% a yearPrice -93.5% | +207.3%+11.9% a yearPrice +135.9% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
AGENAgenusJNJJohnson & Johnson
| Price | $6.17 | $271.31 |
|---|---|---|
| Market value | $386M | $654B |
| Enterprise value (EV) | – | $681B |
| P/E | 13.1 | 40.6 |
| P/E, 5-year median | – | 21.9 |
| P/B | – | 8.0 |
| EV/EBIT | – | 38.4 |
| Free cash flow yield | – | 3.2% |
| Revenue, 12 months | $134M | $99.3B |
|---|---|---|
| Net income, 12 months | $29M | $16.1B |
| Free cash flow, 12 months | -$104M | $20.6B |
| Earnings per share, 12 months | $0.47 | $6.59 |
| Revenue growth, year on year | 10.4% | 6.1% |
| Revenue growth a year, past | +5.3%over 5 years | +2.7%over 5 years |
| EPS growth a year, past | – | +14.9%over 5 years |
| Gross margin | 100.0% | 67.6% |
|---|---|---|
| Operating margin | 38.9% | – |
| Net margin | 22.0% | 16.2% |
| ROIC | – | 12.4% |
| ROE | – | 19.7% |
| Cash | $87M | $17.2B |
|---|---|---|
| Total debt | – | $44.7B |
| Net debt / EBITDA | – | 1.1 |
| Interest cover | 0.9× | 18.0× |
| Dividend yield | – | 2.0% |
|---|---|---|
| Dividend per share, 12 months | – | $5.28 |
| Dividend growth a year, past | – | +5.3%over 5 years |
| Buyback yield | – | 0.9% |
| Shareholder yield | – | 2.9% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Johnson & Johnson ($654B) is about 1,691.8 times Agenus ($386M), at today's prices.
Since November 21, 2016, AGEN's price moved -93.5% and JNJ's +135.9%. With dividends: AGEN -93.5% (-23.9% a year), JNJ +207.3% (+11.9% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Agenus and 1.95% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.
At today's price, the P/E is 13.1 for AGEN and 40.6 for JNJ. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 22.0% for Agenus and 16.2% for Johnson & Johnson, and the operating margin 38.9% and –. Revenue was $134M and $99.3B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.